Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The hypothesis of this study is that a Ketamine / Propofol mixture will produce more stable hemodynamics as compared to Etomidate during emergent intubations in the intensive care unit. Patients that require a breathing tube to be placed in the ICU will be randomized to receIve either a Ketamine / Propofol mixture or Etomidate for sedation in order to place the breathing tube.
Endotracheal intubation is a procedure that may cause significant hemodynamic perturbations and can severely impact the outcome of the critically ill. To ensure a safe outcome during this particular procedure, there are many factors that the clinician is faced with. One decision that confronts the critical care physician involves the correct combination of medications with which to facilitate such a safe outcome. Given the reported hemodynamic stability, etomidate is a medication that is chosen by many providers in this particular situation. However, its association with a possible increase in mortality makes it less than ideal for a number of critical care physicians. In recent years, an admixture of propofol and ketamine has been studied that demonstrates hemodynamic stability based on the balancing of the hemodynamic effects of these two individual agents alone. This novel medication combination, sometimes referred to as "ketofol", may offer a valuable alternative to the critical care physician. Therefore, a randomized parallel-group clinical trial of adult critically ill patients admitted to a medical and/or surgical intensive care unit at Mayo Clinic Rochester who meet the criteria designated below for which urgent and/or emergent intubation is needed will receive one of two interventions based on stratified randomization. The "active" intervention arm will receive ketamine/propofol (ketofol) to facilitate endotracheal intubation. The comparison arm will receive etomidate. The primary outcome will focus on hemodynamic data recorded during the first 5 minutes post-administration with secondary outcomes looking at hemodynamic data at 10 and 15 minutes and addressing intensive care unit length of stay, mortality, adrenal function, and vasoactive medication use, among others.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Etomidate | Active Comparator | weight based dose of 0.15mg/kg |
|
| Ketamine / Propofol Admixture | Experimental | weight based dose of 0.5mg/kg of ketamine and 0.5mg/kg of propofol |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Ketamine / Propofol Admixture | Drug |
| ||
| Etomidate |
| Measure | Description | Time Frame |
|---|---|---|
| Mean Arterial Pressure | Mean arterial pressure for the ketamine/propofol group at a 1:1 dose ratio compared to the etomidate group within the first 15 minutes post-administration in patients in need of urgent and/or emergent endotracheal intubation, as defined by any intubation within the intensive care unit excluding intubations for elective procedural events and codes. | baseline and every 5 minutes up to 15 minutes minutes post study drug administration |
| Measure | Description | Time Frame |
|---|---|---|
| Mortality | In-hospital/28 day mortality among patients in ketamine/propofol combination compared to in-hospital/28-day mortality in etomidate. | Hospital Discharge or Day 28, whichever comes first |
| Vasopressor Use |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Nathan J Smischney, MD | Mayo Clinic | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Mayo Clinic | Rochester | Minnesota | 55905 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 38403984 | Derived | Smischney NJ, Seisa MO, Schroeder DR. Association of Shock Indices with Peri-Intubation Hypotension and Other Outcomes: A Sub-Study of the KEEP PACE Trial. J Intensive Care Med. 2024 Sep;39(9):866-874. doi: 10.1177/08850666241235591. Epub 2024 Feb 25. | |
| 31335755 | Derived | Smischney NJ, Nicholson WT, Brown DR, Gallo De Moraes A, Hoskote SS, Pickering B, Oeckler RA, Iyer VN, Gajic O, Schroeder DR, Bauer PR. Ketamine/propofol admixture vs etomidate for intubation in the critically ill: KEEP PACE Randomized clinical trial. J Trauma Acute Care Surg. 2019 Oct;87(4):883-891. doi: 10.1097/TA.0000000000002448. |
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Etomidate | Etomidate 0.15mg/kg weight based dose |
| FG001 | Ketamine / Propofol Admixture | Ketamine / Propofol Admixture; weight based dose 0.5 mg/kg ketamine and 0.5 mg/kg propofol. |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Etomidate | Etomidate 0.15mg/kg weight based dose |
| BG001 | Ketamine / Propofol Admixture | Ketamine / Propofol Admixture weight based dose 0.5 mg/kg ketamine and 0.5 mg/kg propofol |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Mean Arterial Pressure | Mean arterial pressure for the ketamine/propofol group at a 1:1 dose ratio compared to the etomidate group within the first 15 minutes post-administration in patients in need of urgent and/or emergent endotracheal intubation, as defined by any intubation within the intensive care unit excluding intubations for elective procedural events and codes. | Data are presented for patients who had blood pressure measurements at baseline (within 15 minutes prior to study drug administration). | Posted | Mean | Standard Deviation | mm Hg | baseline and every 5 minutes up to 15 minutes minutes post study drug administration |
|
Given the context of the study and the emergent nature in which the interventions were conducted, adverse events were collected up to 72 hours after enrollment.
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Etomidate | Etomidate 0.15mg/kg weight based dose | 26 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Cardiac arrest | Cardiac disorders | Systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Intubation Complication | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
Single center study with non-blinded interventions and non-controlled co-interventions all of which can impact hemodynamics. Selection bias with 92 non-enrollees.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr. Nathan Smischney | Mayo Clinic | 507-255-4305 | smischney.nathan@mayo.edu |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Aug 30, 2018 | Dec 19, 2018 | Prot_SAP_000.pdf |
Not provided
| ID | Term |
|---|---|
| D016638 | Critical Illness |
| ID | Term |
|---|---|
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D007649 | Ketamine |
| D005045 | Etomidate |
| ID | Term |
|---|---|
| D003510 | Cyclohexanes |
| D003516 | Cycloparaffins |
| D006840 | Hydrocarbons, Alicyclic |
| D006844 | Hydrocarbons, Cyclic |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
|
The use of vasoactive medications to restore the blood pressure post-administration in the ketamine/propofol combination as compared to the etomidate group.
| up to 24 hours post study drug administration |
| Number of Participants With Adrenal Insufficiency | Incidence of adrenal insufficiency between ketamine/propofol admixture and etomidate. Adrenal insuffiency was evaluated with co-syntropin stimulation test. | up to 24 hours post study drug administration |
| Mechanical Ventilation Free Days | comparison of mechanical ventilation free days between the two groups | hospital discharge or day 28, whichever comes first |
| Blood Product Transfusions | blood product transfusions [Red Blood Cells vs. non-Red Blood Cells] between the two groups | hospital discharge or day 28, whichever comes first |
| Intensive Care Unit Free Days | comparison of intensive care unit free days between the two groups | hospital discharge or day 28, whichever comes first |
| Number of Participants Experiencing Delirium Using Confusion Assessment Method in ICU | Comparison of number of participants who were positive for delirium using CAM-ICU between groups | up to 24 hours post study drug administration |
| 25909406 | Derived | Smischney NJ, Hoskote SS, Gallo de Moraes A, Racedo Africano CJ, Carrera PM, Tedja R, Pannu JK, Hassebroek EC, Reddy DR, Hinds RF, Thakur L. Ketamine/propofol admixture (ketofol) at induction in the critically ill against etomidate (KEEP PACE trial): study protocol for a randomized controlled trial. Trials. 2015 Apr 21;16:177. doi: 10.1186/s13063-015-0687-0. |
| BG002 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
Ketamine / Propofol Admixture weight based dose 0.5 mg/kg ketamine and 0.5 mg/kg propofol |
|
|
|
| Secondary | Mortality | In-hospital/28 day mortality among patients in ketamine/propofol combination compared to in-hospital/28-day mortality in etomidate. | Posted | Count of Participants | Participants | Hospital Discharge or Day 28, whichever comes first |
|
|
|
|
| Secondary | Vasopressor Use | The use of vasoactive medications to restore the blood pressure post-administration in the ketamine/propofol combination as compared to the etomidate group. | Data are presented for patients who had vasopressor data within the time frame | Posted | Count of Participants | Participants | up to 24 hours post study drug administration |
|
|
|
|
| Secondary | Number of Participants With Adrenal Insufficiency | Incidence of adrenal insufficiency between ketamine/propofol admixture and etomidate. Adrenal insuffiency was evaluated with co-syntropin stimulation test. | A secondary outcome included adrenal testing in a subset of patients. Thus, cortisol levels were available for 29 subjects at 3 and 5 hours and 30 subjects at 23 and 25 hours. | Posted | Count of Participants | Participants | up to 24 hours post study drug administration |
|
|
|
| Secondary | Mechanical Ventilation Free Days | comparison of mechanical ventilation free days between the two groups | Posted | Median | Inter-Quartile Range | days | hospital discharge or day 28, whichever comes first |
|
|
|
|
| Secondary | Blood Product Transfusions | blood product transfusions [Red Blood Cells vs. non-Red Blood Cells] between the two groups | Posted | Count of Participants | Participants | hospital discharge or day 28, whichever comes first |
|
|
|
|
| Secondary | Intensive Care Unit Free Days | comparison of intensive care unit free days between the two groups | Posted | Median | Inter-Quartile Range | days | hospital discharge or day 28, whichever comes first |
|
|
|
|
| Secondary | Number of Participants Experiencing Delirium Using Confusion Assessment Method in ICU | Comparison of number of participants who were positive for delirium using CAM-ICU between groups | The analysis of new onset delirium was restricted to subjects (54 etomidate, 62 KPA) who did not experience delirium pre-study drug. | Posted | Count of Participants | Participants | up to 24 hours post study drug administration |
|
|
|
|
| 73 |
| 6 |
| 73 |
| 19 |
| 73 |
| EG001 | Ketamine / Propofol Admixture | Ketamine / Propofol Admixture weight based dose 0.5 mg/kg ketamine and 0.5 mg/kg propofol | 25 | 79 | 5 | 79 | 14 | 79 |
| Hypertensive urgency | Vascular disorders | Systematic Assessment |
|
| Severe hypotension | Vascular disorders | Systematic Assessment |
|
| IV infiltration | General disorders | Systematic Assessment |
|
| Multi organ failure | General disorders | Systematic Assessment |
|
| Respiratory failure | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Tachycardia | Cardiac disorders | Systematic Assessment |
|
| Vomiting/Aspiration | General disorders | Systematic Assessment |
|
| arrythmia | Cardiac disorders | Systematic Assessment |
|
| shock | Vascular disorders | Systematic Assessment |
|
Not provided
Not provided
Not provided
| D006838 |
| Hydrocarbons |
| D009930 | Organic Chemicals |
| D007093 | Imidazoles |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| New-onset pressors (within 3 minutes) |
|
|
| Delayed-onset pressors (within 24 hours) |
|
|
| 0.308 |
| Superiority |
| Delayed-onset pressors (within 24 hrs) | ANCOVA | 0.691 | Superiority |
| Colloid |
|
| 0.046 |
| Superiority |
| Colloid | ANCOVA | 0.502 | Superiority |